Plexxikon strikes $100M collaboration pact

Plexxikon and France's Servier have struck a collaboration deal to discover non-peptidic renin inhibitors. Renin is an enzyme known to play a direct role in hypertension, renal failure and vascular disease. Under the terms of the agreement, Plexxikon will receive an upfront payment, research funding, and potential milestone payments totaling over $100 million. Servier will be responsible for clinical development and commercialization of the products and will receive an exclusive worldwide license for any renin inhibitors discovered through the collaboration in the field of cardiovascular disease, including hypertension.

- see the release on the agreement

PLUS: XOMA and Affimed Therapeutics announced today that they have signed a cross-license and collaboration agreement for antibody-related technologies. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.